Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Hyrulean King who wrote (281)	6/12/1998 10:08:00 AM
From: chirodoc	Respond to of 5402

<<<<do you know if the phase 1 product that had fda approval was compatible w/ all blood types? This seems to be a key item for the testing. ..as far as i know it was ....go to yahoo--go to sgnc--go to edgar .....lots of info on this stock good luck off to work curtis

To: Hyrulean King who wrote (281)	6/12/1998 10:10:00 AM
From: Lee Walsh	Respond to of 5402

FROM SEC Filings: PHER-O2 is believed to have the following advantages over humanblood: 1. May carry three to four times the oxygen of human blood per unit 2. Free of HIV, hepatitis and other blood-borne disease; 3. Universal match for all blood types; 4. May be mass-produced; 5. Has a three-year shelf life; 6. May be stored at room temperature; 7. Has controllable circulatory half-life; and 8. 1/900th the size of a red blood cell. 9. PHER-O2 is a second generation drug from Fluosol-DA, the only synthetic red blood cell approved by the Food and Drug Administration.